Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function
Identifieur interne : 006836 ( Main/Merge ); précédent : 006835; suivant : 006837Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function
Auteurs : Fiona J. Warner [Australie, Royaume-Uni] ; Jodie L. Guy [Royaume-Uni] ; Dan W. Lambert [Royaume-Uni] ; Nigel M. Hooper [Royaume-Uni] ; Anthony J. Turner [Royaume-Uni]Source :
- Letters in Peptide Science [ 0929-5666 ] ; 2003-11-01.
English descriptors
- KwdEn :
Abstract
Abstract: Angiotensin converting enzyme-2 (ACE2) is a recently described homologue of the vasoactive peptidase, angiotensin converting enzyme (ACE). Like ACE, ACE2 is an integral (type I) membrane zinc metallopeptidase, which exists as an ectoenzyme. ACE2 is less widely distributed than ACE in the body, being expressed at highest concentrations in the heart, kidney and testis. ACE2 also differs from ACE in its substrate specificity, functioning exclusively as a carboxypeptidase rather than a peptidyl dipeptidase. A key role for ACE2 appears to be emerging in the conversion of angiotensin II to angiotensin (1–7), allowing it to act as a counter-balance to the actions of ACE. ACE2 has been localised to the endothelial and epithelial cells of the heart and kidney where it may have a role at the cell surface in hydrolysing bioactive peptides such as angiotensin II present in the circulation. A role for ACE2 in the metabolism of other biologically active peptides also needs to be considered. ACE2 also serendipitously appears to act as a receptor for the severe acute respiratory syndrome (SARS) coronavirus. Studies using ace2 -/- mice, and other emerging studies in vivo and in vitro, have revealed that ACE2 has important functions in cardiac regulation and diabetes. Together with its role as a SARS receptor, ACE2 is therefore likely to be an important therapeutic target in a diverse range of disease states.
Url:
DOI: 10.1007/s10989-004-2387-6
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C22
- to stream Istex, to step Curation: 000C22
- to stream Istex, to step Checkpoint: 002334
Links to Exploration step
ISTEX:FF302EBE21EA0ED51392DB1B8572F63B8099FCB6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function</title>
<author><name sortKey="Warner, Fiona J" sort="Warner, Fiona J" uniqKey="Warner F" first="Fiona J." last="Warner">Fiona J. Warner</name>
</author>
<author><name sortKey="Guy, Jodie L" sort="Guy, Jodie L" uniqKey="Guy J" first="Jodie L." last="Guy">Jodie L. Guy</name>
</author>
<author><name sortKey="Lambert, Dan W" sort="Lambert, Dan W" uniqKey="Lambert D" first="Dan W." last="Lambert">Dan W. Lambert</name>
</author>
<author><name sortKey="Hooper, Nigel M" sort="Hooper, Nigel M" uniqKey="Hooper N" first="Nigel M." last="Hooper">Nigel M. Hooper</name>
</author>
<author><name sortKey="Turner, Anthony J" sort="Turner, Anthony J" uniqKey="Turner A" first="Anthony J." last="Turner">Anthony J. Turner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FF302EBE21EA0ED51392DB1B8572F63B8099FCB6</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1007/s10989-004-2387-6</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-FR4V69LL-T/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C22</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C22</idno>
<idno type="wicri:Area/Istex/Curation">000C22</idno>
<idno type="wicri:Area/Istex/Checkpoint">002334</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002334</idno>
<idno type="wicri:doubleKey">0929-5666:2003:Warner F:angiotensin:converting:enzyme</idno>
<idno type="wicri:Area/Main/Merge">006836</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function</title>
<author><name sortKey="Warner, Fiona J" sort="Warner, Fiona J" uniqKey="Warner F" first="Fiona J." last="Warner">Fiona J. Warner</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker Heart Research Institute, Peptide Biology, 3004, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Australie</country>
</affiliation>
</author>
<author><name sortKey="Guy, Jodie L" sort="Guy, Jodie L" uniqKey="Guy J" first="Jodie L." last="Guy">Jodie L. Guy</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lambert, Dan W" sort="Lambert, Dan W" uniqKey="Lambert D" first="Dan W." last="Lambert">Dan W. Lambert</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hooper, Nigel M" sort="Hooper, Nigel M" uniqKey="Hooper N" first="Nigel M." last="Hooper">Nigel M. Hooper</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Turner, Anthony J" sort="Turner, Anthony J" uniqKey="Turner A" first="Anthony J." last="Turner">Anthony J. Turner</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, LS2 9JT, Leeds</wicri:regionArea>
<orgName type="university">Université de Leeds</orgName>
<placeName><settlement type="city">Leeds</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Yorkshire-et-Humber</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Letters in Peptide Science</title>
<title level="j" type="abbrev">Int J Pept Res Ther</title>
<idno type="ISSN">0929-5666</idno>
<idno type="eISSN">1573-496X</idno>
<imprint><publisher>Kluwer Academic Publishers</publisher>
<pubPlace>Dordrecht</pubPlace>
<date type="published" when="2003-11-01">2003-11-01</date>
<biblScope unit="volume">10</biblScope>
<biblScope unit="issue">5-6</biblScope>
<biblScope unit="page" from="377">377</biblScope>
<biblScope unit="page" to="385">385</biblScope>
</imprint>
<idno type="ISSN">0929-5666</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0929-5666</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ACE2</term>
<term>SARS</term>
<term>angiotensin-converting enzyme</term>
<term>apelin</term>
<term>bradykinin</term>
<term>diabetes</term>
<term>heart</term>
<term>hypertension</term>
<term>kidney</term>
<term>renin-angiotensin</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Angiotensin converting enzyme-2 (ACE2) is a recently described homologue of the vasoactive peptidase, angiotensin converting enzyme (ACE). Like ACE, ACE2 is an integral (type I) membrane zinc metallopeptidase, which exists as an ectoenzyme. ACE2 is less widely distributed than ACE in the body, being expressed at highest concentrations in the heart, kidney and testis. ACE2 also differs from ACE in its substrate specificity, functioning exclusively as a carboxypeptidase rather than a peptidyl dipeptidase. A key role for ACE2 appears to be emerging in the conversion of angiotensin II to angiotensin (1–7), allowing it to act as a counter-balance to the actions of ACE. ACE2 has been localised to the endothelial and epithelial cells of the heart and kidney where it may have a role at the cell surface in hydrolysing bioactive peptides such as angiotensin II present in the circulation. A role for ACE2 in the metabolism of other biologically active peptides also needs to be considered. ACE2 also serendipitously appears to act as a receptor for the severe acute respiratory syndrome (SARS) coronavirus. Studies using ace2 -/- mice, and other emerging studies in vivo and in vitro, have revealed that ACE2 has important functions in cardiac regulation and diabetes. Together with its role as a SARS receptor, ACE2 is therefore likely to be an important therapeutic target in a diverse range of disease states.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006836 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006836 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:FF302EBE21EA0ED51392DB1B8572F63B8099FCB6 |texte= Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function }}
This area was generated with Dilib version V0.6.33. |